A cost-effective alternative for treating staphylococcal bloodstream infections

Research comparing clinical outcomes between patients receiving nafcillin and cefazolin for treatment of methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia shows that overall treatment failure rate among patients receiving cefazolin was no worse than nafcillin, and significantly fewer adverse effects were documented for those receiving cefazolin.

from Today's Healthcare News -- ScienceDaily http://ift.tt/1Qu6kYO